cohort_definition_id,cohort_name,age_group,sex,days_prior_observation,start_date,end_date,target_cohort_definition_id,target_cohort_name,number_records,number_subjects,reason_id,reason,excluded_records,excluded_subjects,cdm_name,result_type,cohort_table_name
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
1,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
2,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
3,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
4,Denominator cohort 4,0 to 2,Both,0,2002-01-01,2022-12-31,1,IBD,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",539,539,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
5,Denominator cohort 5,0 to 2,Male,0,2002-01-01,2022-12-31,1,IBD,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",233,233,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
6,Denominator cohort 6,0 to 2,Female,0,2002-01-01,2022-12-31,1,IBD,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",306,306,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
7,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,8,8,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",531,531,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
8,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,4,4,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",229,229,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
9,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,4,4,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",302,302,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
10,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,16,16,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",523,523,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
11,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,11,11,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",222,222,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
12,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",301,301,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
13,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,70,70,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",469,469,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
14,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,32,32,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",201,201,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
15,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,38,38,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",268,268,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
16,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,95,95,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",444,444,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
17,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,41,41,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",192,192,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
18,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,54,54,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",252,252,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
19,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,83,83,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",456,456,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
20,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,33,33,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",200,200,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
21,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,50,50,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",256,256,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
22,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,84,84,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",455,455,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
23,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,35,35,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",198,198,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
24,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,49,49,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",257,257,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
25,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,89,89,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",450,450,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
26,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,37,37,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",196,196,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
27,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,52,52,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",254,254,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
28,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,60,60,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",479,479,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
29,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,26,26,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",207,207,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
30,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,34,34,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",272,272,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
31,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,34,34,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",505,505,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
32,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,14,14,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",219,219,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
33,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,20,20,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",286,286,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
34,Denominator cohort 34,90 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",539,539,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
35,Denominator cohort 35,90 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",233,233,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
36,Denominator cohort 36,90 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",306,306,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
37,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
38,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
39,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
40,Denominator cohort 40,0 to 2,Both,0,2002-01-01,2022-12-31,2,IBD_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",539,539,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
41,Denominator cohort 41,0 to 2,Male,0,2002-01-01,2022-12-31,2,IBD_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",233,233,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
42,Denominator cohort 42,0 to 2,Female,0,2002-01-01,2022-12-31,2,IBD_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",306,306,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
43,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,8,8,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",531,531,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
44,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,4,4,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",229,229,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
45,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,4,4,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",302,302,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
46,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,16,16,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",523,523,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
47,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,11,11,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",222,222,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
48,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",301,301,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
49,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,70,70,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",469,469,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
50,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,32,32,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",201,201,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
51,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,38,38,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",268,268,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
52,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,95,95,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",444,444,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
53,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,41,41,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",192,192,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
54,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,54,54,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",252,252,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
55,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,83,83,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",456,456,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
56,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,33,33,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",200,200,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
57,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,50,50,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",256,256,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
58,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,84,84,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",455,455,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
59,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,35,35,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",198,198,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
60,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,49,49,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",257,257,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
61,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,89,89,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",450,450,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
62,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,37,37,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",196,196,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
63,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,52,52,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",254,254,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
64,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,60,60,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",479,479,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
65,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,26,26,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",207,207,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
66,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,34,34,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",272,272,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
67,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,34,34,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",505,505,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
68,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,14,14,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",219,219,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
69,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,20,20,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",286,286,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
70,Denominator cohort 70,90 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",539,539,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,233,233,8,Not Male,306,306,PHARMETRICS_100k,Cohort details,denominator_target
71,Denominator cohort 71,90 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",233,233,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,539,539,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,306,306,8,Not Female,233,233,PHARMETRICS_100k,Cohort details,denominator_target
72,Denominator cohort 72,90 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",306,306,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
73,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
74,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
75,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
76,Denominator cohort 76,0 to 2,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",894,894,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
77,Denominator cohort 77,0 to 2,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",387,387,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
78,Denominator cohort 78,0 to 2,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",507,507,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
79,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",889,889,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
80,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,1,1,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",386,386,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
81,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,4,4,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",503,503,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
82,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,13,13,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",881,881,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
83,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",382,382,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
84,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,8,8,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",499,499,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
85,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,84,84,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",810,810,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
86,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,31,31,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",356,356,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
87,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,53,53,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",454,454,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
88,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,109,109,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",785,785,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
89,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,47,47,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",340,340,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
90,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,62,62,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",445,445,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
91,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,148,148,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",746,746,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
92,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,72,72,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",315,315,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
93,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,76,76,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",431,431,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
94,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,178,178,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",716,716,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
95,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,78,78,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",309,309,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
96,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,100,100,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",407,407,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
97,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,186,186,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",708,708,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
98,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,83,83,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",304,304,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
99,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,103,103,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",404,404,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
100,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,114,114,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",780,780,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
101,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,50,50,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",337,337,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
102,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,64,64,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",443,443,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
103,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,57,57,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",837,837,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
104,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,20,20,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",367,367,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
105,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,37,37,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",470,470,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
106,Denominator cohort 106,90 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",894,894,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
107,Denominator cohort 107,90 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",387,387,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
108,Denominator cohort 108,90 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",507,507,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
109,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
110,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
111,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
112,Denominator cohort 112,0 to 2,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",894,894,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
113,Denominator cohort 113,0 to 2,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",387,387,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
114,Denominator cohort 114,0 to 2,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",507,507,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
115,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",889,889,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
116,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,1,1,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",386,386,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
117,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,4,4,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",503,503,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
118,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,13,13,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",881,881,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
119,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",382,382,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
120,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,8,8,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",499,499,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
121,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,84,84,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",810,810,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
122,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,31,31,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",356,356,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
123,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,53,53,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",454,454,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
124,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,109,109,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",785,785,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
125,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,47,47,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",340,340,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
126,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,62,62,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",445,445,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
127,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,148,148,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",746,746,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
128,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,72,72,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",315,315,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
129,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,76,76,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",431,431,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
130,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,178,178,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",716,716,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
131,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,78,78,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",309,309,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
132,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,100,100,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",407,407,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
133,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,186,186,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",708,708,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
134,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,83,83,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",304,304,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
135,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,103,103,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",404,404,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
136,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,114,114,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",780,780,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
137,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,50,50,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",337,337,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
138,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,64,64,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",443,443,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
139,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,57,57,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",837,837,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
140,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,20,20,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",367,367,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
141,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,37,37,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",470,470,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
142,Denominator cohort 142,90 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",894,894,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,387,387,8,Not Male,507,507,PHARMETRICS_100k,Cohort details,denominator_target
143,Denominator cohort 143,90 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",387,387,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,894,894,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,507,507,8,Not Female,387,387,PHARMETRICS_100k,Cohort details,denominator_target
144,Denominator cohort 144,90 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",507,507,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
145,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
146,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
147,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
148,Denominator cohort 148,0 to 2,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",209,209,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
149,Denominator cohort 149,0 to 2,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
150,Denominator cohort 150,0 to 2,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",123,123,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
151,Denominator cohort 151,3 to 12,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",209,209,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
152,Denominator cohort 152,3 to 12,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
153,Denominator cohort 153,3 to 12,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",123,123,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
154,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,1,1,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",208,208,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
155,Denominator cohort 155,13 to 17,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
156,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,1,1,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",122,122,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
157,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,7,7,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",202,202,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
158,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",81,81,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
159,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,2,2,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",121,121,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
160,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,23,23,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",186,186,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
161,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,9,9,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",77,77,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
162,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,14,14,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",109,109,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
163,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,35,35,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",174,174,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
164,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,18,18,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",68,68,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
165,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,17,17,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",106,106,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
166,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,52,52,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",157,157,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
167,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,22,22,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",64,64,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
168,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,30,30,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",93,93,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
169,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,50,50,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",159,159,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
170,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,18,18,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",68,68,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
171,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,32,32,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",91,91,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
172,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,30,30,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",179,179,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
173,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,11,11,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",75,75,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
174,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,19,19,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",104,104,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
175,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,11,11,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",198,198,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
176,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,3,3,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",83,83,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
177,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,8,8,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",115,115,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
178,Denominator cohort 178,90 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",209,209,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
179,Denominator cohort 179,90 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
180,Denominator cohort 180,90 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",123,123,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
181,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
182,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
183,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",0,0,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
184,Denominator cohort 184,0 to 2,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",209,209,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
185,Denominator cohort 185,0 to 2,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
186,Denominator cohort 186,0 to 2,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",123,123,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
187,Denominator cohort 187,3 to 12,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",209,209,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
188,Denominator cohort 188,3 to 12,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
189,Denominator cohort 189,3 to 12,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",123,123,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
190,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,1,1,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",208,208,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
191,Denominator cohort 191,13 to 17,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
192,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,1,1,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",122,122,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
193,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,7,7,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",202,202,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
194,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,5,5,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",81,81,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
195,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,2,2,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",121,121,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
196,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,23,23,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",186,186,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
197,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,9,9,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",77,77,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
198,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,14,14,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",109,109,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
199,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,35,35,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",174,174,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
200,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,18,18,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",68,68,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
201,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,17,17,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",106,106,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
202,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,52,52,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",157,157,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
203,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,22,22,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",64,64,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
204,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,30,30,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",93,93,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
205,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,50,50,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",159,159,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
206,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,18,18,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",68,68,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
207,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,32,32,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",91,91,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
208,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,30,30,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",179,179,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
209,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,11,11,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",75,75,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
210,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,19,19,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",104,104,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
211,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,11,11,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",198,198,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
212,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,3,3,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",83,83,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
213,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,8,8,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",115,115,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
214,Denominator cohort 214,90 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",209,209,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,86,86,8,Not Male,123,123,PHARMETRICS_100k,Cohort details,denominator_target
215,Denominator cohort 215,90 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",86,86,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,1,Starting population,NA,NA,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,2,Missing year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,3,Missing sex,0,0,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,4,Cannot satisfy age criteria during the study period based on year of birth,0,0,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,5,No observation time available during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,6,Doesn't satisfy age criteria during the study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,209,209,7,Prior history requirement not fulfilled during study period,0,0,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,123,123,8,Not Female,86,86,PHARMETRICS_100k,Cohort details,denominator_target
216,Denominator cohort 216,90 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,0,0,10,"No observation time available after applying age, prior observation and, if applicable, target criteria",123,123,PHARMETRICS_100k,Cohort details,denominator_target
